[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 370, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq., J.D.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1970938, "exercisedValue": 0, "unexercisedValue": 26229992}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 780600, "exercisedValue": 0, "unexercisedValue": 8840500}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 32.46, "open": 32.29, "dayLow": 31.584, "dayHigh": 32.56, "regularMarketPreviousClose": 32.46, "regularMarketOpen": 32.29, "regularMarketDayLow": 31.584, "regularMarketDayHigh": 32.56, "payoutRatio": 0.0, "beta": 1.881, "trailingPE": 84.63158, "forwardPE": 33.154636, "volume": 2350906, "regularMarketVolume": 2350906, "averageVolume": 2132116, "averageVolume10days": 2282500, "averageDailyVolume10Day": 2282500, "bid": 32.08, "ask": 32.25, "bidSize": 5, "askSize": 5, "marketCap": 5102698496, "fiftyTwoWeekLow": 21.16, "fiftyTwoWeekHigh": 46.48, "priceToSalesTrailing12Months": 11.237717, "fiftyDayAverage": 32.5319, "twoHundredDayAverage": 34.410374, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4694655488, "profitMargins": 0.13315, "floatShares": 135140097, "sharesOutstanding": 158666000, "sharesShort": 24510079, "sharesShortPriorMonth": 23442551, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.1545, "heldPercentInsiders": 0.09731, "heldPercentInstitutions": 0.64635, "shortRatio": 8.92, "shortPercentOfFloat": 0.202, "impliedSharesOutstanding": 158666000, "bookValue": 1.903, "priceToBook": 16.899632, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "earningsQuarterlyGrowth": 3.098, "netIncomeToCommon": 60458000, "trailingEps": 0.38, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 10.339, "enterpriseToEbitda": 54.66, "52WeekChange": 0.29208517, "SandP52WeekChange": 0.16885936, "quoteType": "EQUITY", "currentPrice": 32.16, "targetHighPrice": 53.0, "targetLowPrice": 11.0, "targetMeanPrice": 40.5, "targetMedianPrice": 46.0, "recommendationKey": "none", "numberOfAnalystOpinions": 6, "totalCash": 251870000, "totalCashPerShare": 1.726, "ebitda": 85889000, "totalDebt": 254526000, "quickRatio": 2.812, "currentRatio": 3.863, "totalRevenue": 454068992, "debtToEquity": 92.075, "revenuePerShare": 3.111, "returnOnAssets": 0.09722, "returnOnEquity": 0.26633, "grossProfits": 394848992, "freeCashflow": -86542496, "operatingCashflow": -59125000, "earningsGrowth": 3.25, "revenueGrowth": 0.921, "grossMargins": 0.86958003, "ebitdaMargins": 0.18915, "operatingMargins": 0.24685, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.924212, "regularMarketPrice": 32.16, "corporateActions": [], "postMarketTime": 1757710640, "regularMarketTime": 1757707200, "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "marketState": "CLOSED", "epsTrailingTwelveMonths": 0.38, "epsForward": 0.97, "epsCurrentYear": 0.75597, "priceEpsCurrentYear": 42.54137, "fiftyDayAverageChange": -0.37189865, "fiftyDayAverageChangePercent": -0.011431815, "twoHundredDayAverageChange": -2.2503738, "twoHundredDayAverageChangePercent": -0.06539812, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": 0.0, "fiftyTwoWeekLowChange": 11.0, "fiftyTwoWeekLowChangePercent": 0.51984876, "fiftyTwoWeekRange": "21.16 - 46.48", "fiftyTwoWeekHighChange": -14.32, "fiftyTwoWeekHighChangePercent": -0.3080895, "fiftyTwoWeekChangePercent": 29.208517, "earningsTimestamp": 1754310600, "earningsTimestampStart": 1762259400, "earningsTimestampEnd": 1762259400, "earningsCallTimestampStart": 1754310600, "earningsCallTimestampEnd": 1754310600, "isEarningsDateEstimate": true, "postMarketPrice": 32.16, "postMarketChange": 0.0, "regularMarketChange": -0.299999, "regularMarketDayRange": "31.584 - 32.56", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2132116, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-13"}]